0.405
-0.01 (-3.34%)
| Previous Close | 0.419 |
| Open | 0.441 |
| Volume | 628,484 |
| Avg. Volume (3M) | 936,023 |
| Market Cap | 28,799,350 |
| Price / Sales | 52.46 |
| Price / Book | 0.490 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Operating Margin (TTM) | -9,653.85% |
| Diluted EPS (TTM) | -0.340 |
| Quarterly Revenue Growth (YOY) | -12.20% |
| Total Debt/Equity (MRQ) | 24.34% |
| Current Ratio (MRQ) | 4.93 |
| Operating Cash Flow (TTM) | -49.55 M |
| Levered Free Cash Flow (TTM) | -27.61 M |
| Return on Assets (TTM) | -31.37% |
| Return on Equity (TTM) | -36.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Ovid Therapeutics Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.63 |
|
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 16.31% |
| % Held by Institutions | 55.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rubric Capital Management Lp | 31 Mar 2025 | 5,315,969 |
| Madison Avenue Partners, Lp | 31 Mar 2025 | 2,465,623 |
| Sio Capital Management, Llc | 31 Mar 2025 | 2,232,000 |
| Acadian Asset Management Llc | 31 Mar 2025 | 2,088,046 |
| Kennedy Capital Management Llc | 31 Mar 2025 | 1,732,865 |
| Driehaus Capital Management Llc | 31 Mar 2025 | 1,400,191 |
| 52 Weeks Range | ||
| Median | 1.50 (270.37%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 May 2025 | 1.50 (270.37%) | Buy | 0.291 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Jun 2025 | Announcement | Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties |
| 05 Jun 2025 | Announcement | Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 |
| 13 May 2025 | Announcement | Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |